I-LOVE-IT 2:

A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Bo Xu, MD

On behalf of the I-LOVE-IT 2 Trial Investigators Fu Wai Hospital, National Center for Cardiovascular Diseases Beijing, China



12:00 PM-12:10 PM, Tuesday, September 16th, 2014 Washington DC, USA



- NewYork-Presbyterian

Financial Disclosures

- The study was sponsored by Essen Technology (Beijing, China), and was also supported by National Key Technology R&D Program in the 12th Five-Year Plan of China (2011BAI11B07) and Key Project of National 12th Five-Year Research Program of China (2012ZX093016 - 002)
- > All of the authors have no relevant personal conflicts of interest to disclose

Author

Institute/Hospital

Yaling Han, MD General Hospital of Shenyang Military Region, Shenyang, China Bo Xu, MD Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China Quanmin Jing, MD General Hospital of Shenyang Military Region, Shenyang, China Shuzheng Lu, MD Affiliated Anzhen Hospital of Capital Medical University, Beijing, China Lixia Yang, MD General Hospital of Chengdu Military Region, Kunming, China Kai Xu, MD General Hospital of Shenyang Military Region, Shenyang, China Yi Li, MD General Hospital of Shenyang Military Region, Shenyang, China Jing Li, MD General Hospital of Shenyang Military Region, Shenyang, China Changdong Guan, MSc Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China Ajay J. Kirtane, MD, SM Columbia University Medical Center / New York Presbyterian Hospital, New York, NY Yuejin Yang, MD Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China





Background

- No randomized trials have compared safety and efficacy of biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable polymer-coated sirolimus-eluting stent (DP-SES) on similar cobalt-chromium platforms, thereby isolating the effect of the polymer type
- Moreover, optimal duration of dual antiplatelet therapy (DAPT) after BP-SES implantation remains underdetermined



Stefanini GG, et al, *Eur Heart J* 2012 Christiansen EH, et al, *Lancet* 2013



Comparison of Specifications between BP-SES and DP-SES



Tivoli®



Firebird 2TM

Manufactory Stent Platform Material Strut Thickness Stent Profile Diameter

Length

Drug

Drug Dose

Polymer

Polymer Thickness

Drug Release

tct2014

Essen Technology, Beijing, China

Cobalt-Chromium (L605)

0.080 mm < 1.10 mm 2.50, 2.75, 3.00, 3.50, 4.00 mm 10, 15, 18, 21, 25, 30, 35 mm Sirolimus 8 μg/mm PLGA (biodegradable) 5.5 μm 75% at 28 days

MicroPort, Shanghai, China Cobalt-Chromium (L605) 0.086 mm < 1.12 mm 2.50, 2.75, 3.00, 3.50, 4.00 mm 13, 18, 23, 29, 33 mm Sirolimus 9 µg/mm SBS (durable) 6.0 µm > 80% at 30 days



Objectives

- To investigate the hypothesis that a novel BP-SES (Tivoli, Essen Tech, Beijing, China) is noninferior in safety and efficacy outcomes to a DP-SES (Firebird 2, MicroPort, Shanghai, China)
- To investigate whether the safety and efficacy of 6month DAPT are comparable with 12-month DAPT in patients receiving BP-SES implantations





Study Design



Primary Endpoint: 1-year TLF (composite of cardiac death, TVMI, and CI-TLR)
Major Secondary Endpoints: 1-year TLF and NACCE (composite of death, MI, stroke, major bleeding (BARC >= II)) between 6- and 12-month DAPT groups after BP-SES implantations
Secondary Endpoints: individual TLF components, definite/probable stent thrombosis, device/lesion/procedure success rates, and PoCE (composite of all cause death, all MI, and any revascularization)

*TLF = target lesion failure; TVMI = target vessel myocardial infarction; CI-TLR = clinically indicated target lesion revascularization; NACCE = net adverse clinical and cerebral events; PoCE = patient-oriented composite endpoint





Inclusion Criteria

Major Inclusion:

- ≻ Age ≥18 years
- Chronic, stable coronary artery disease or acute coronary syndromes, including MI with or without ST-segment elevation
- Acceptable candidate for CABG
- At least one *de novo* coronary lesion with diameter stenosis
 ≥ 70% in a vessel with reference diameter ≥ 2.5 mm and ≤ 4.0 mm
- Patients with multivessel disease must receive complete revascularization within 30 days using same study stents if needed





Exclusion Criteria

Major Exclusion:

- Intolerance to a study drug, metal alloys, or contrast media
- Life expectancy less than one year
- Restenotic lesions
- Stent implantation within one year
- Left ventricular ejection fraction < 40%</p>
- Severe renal or hepatic dysfunction, hemodynamic instability
- Planned surgery within 6 months after index procedure
- Childbearing potential within one year
- Clinical indications of inability to tolerate DAPT for 12 months
- Inability to provide written informed consent
- Participation in another trial before reaching the primary endpoint





Statistical Assumption

Primary Endpoint: Target Lesion Failure at 1 year

- > Expected TLF at 1 year in both groups = 8.3%
- > Noninferiority margin = 3.7%
- > One-sided type I error = 0.025
- 2631 patients (1754 patients in BP-SES group and 877 patients in DP-SES group) randomized in a 2:1 ratio would yield at least 90% power to detect noninferiority of BP-SES
- Considering anticipated loss to follow-up of 5%, a total of 2790 subjects would need to be enrolled





Study Organization

Principle Investigator	Yaling Han, MD	
Honorary Chairman	Runlin Gao, MD	
Co-Principle Investigators	Yuejin Yang, MD; Shuzheng Lu, MD	
Executive Committee Directors	Bo Xu, MD; Quanmin Jing, MD	
Clinical Events Committee	Zhujun Shen, MD (Chair); Lefeng Wang, MD; Jingxuan Guo, MD	
Angiographic Core Lab		
Data Management	CCRF, Beijing, China	
Data Monitoring		
Statistical Analysis		
Sponsor	Essen Technology, Beijing, China	






I-LOVE-IT 2 Enrollers

Site PI	Hospital, City	Patients Enrolled	Site PI	Hospital, City	Patients Enrolled
Yaling Han	General Hospital of Shenyang Military Region, Shenyang	690	Zhe Jin	Affiliated Zhongshan Hospital of Dalian University, Dalian	45
Yuejin Yang	Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing	424	Zishan Hou	Linyi People's Hospital, Linyi	31
Lixia Yang	General Hospital of Chengdu Military Region, Kunming	325	Likun Ma	Anhui Provincial Hospital, Hefei	26
Shuzheng Lu	Affiliated Anzhen Hospital of Capital Medical University, Beijing	114	Zhi Zhang	Third Affiliated Hospital of Liaoning Medical College, Jinzhou	24
Qiangsun Zheng	Affiliated Tangdu Hospital of the Fourth Military Medical University, Xi'an	112	Lianmin Wang	Mudanjiang Cardiovascular Hospital, Mudanjiang	22
Xueqi Li	Fourth Affiliated Hospital of Haerbin Medical University, Haerbin	111	Pitian Zhao	Yidu Central Hospital of Weifang City, Weifang	21
Xianxian Zhao	Affiliated Changhai Hospital of the Second Military Medical University, Shanghai	104	Xin Huang	Benxi Central Hospital, Benxi	20
Haichang Wang	Affiliated Xijing Hospital of the Fourth Military Medical University, Xi'an	99	Chunjiang Li	Chinese PLA 202 Hospital, Shenyang	18
Xuezhong Zhao	Jilin University First Hospital, Changchun	89	Yongwei Zhao	Mishan People's Hospital, Mishan	17
Xiaoyan Li	General Hospital of Jinan Military Region, Jinan	71	Jianqiu Liang	Second People's Hospital of Foshan City, Foshan	11
Pengfei Yu	Pingdu People's Hospital, Pingdu	65	Yingxian Sun	Affiliated First Hospital of China Medical University, Shenyang	10
Hongyun Zang	Chinese PLA 463 Hospital, Shenyang	56	Hong Yu	Panjin Central Hospital, Panjin	9
Xuebin Cao	Chinese PLA 252 Hospital, Baoding	52	Shaohong Dong	Shenzhen People's Hospital, Shenzhen	8
Jun Zhang	Cangzhou Central Hospital, Cangzhou	52	Guizhou Tao	First Affiliated Hospital of Liaoning Medical College, Jinzhou	7
Wenyue Pan	Affiliated Shengjing Hospital of China Medical University, Shenyang	50	Zhenshun Xiu	Jimo People's Hospital, Jimo	5
Zhifang Wang	Xinxiang Central Hospital, Xinxiang	48	Chuanyu Gao	Henan Provincial People's Hospital, Zhengzhou	1





Patient Flow



Baseline Patient Characteristics

BP-SES	DP-SES	Р
(n=1829)	(n=908)	,
60.2 ± 10.1	60.2 ± 10.0	0.89
68.0 (1243)	70.0 (636)	0.27
25.2 ± 3.0	25.1 ± 3.0	0.64
22.6 (414)	21.3 (193)	0.41
8.4 (154)	8.0 (73)	0.73
62.9 (1150)	61.6 (559)	0.50
24.3 (445)	204 (22.5)	0.28
5.7 (104)	5.8 (53)	0.87
		0.85
37.5 (685)	36.9 (335)	
11.7 (213)	11.1 (101)	
50.9 (931)	52.0 (472)	
16.5 (301)	16.6 (151)	0.91
9.4 (171)	10.1 (92)	0.51
1.3 (23)	0.4 (4)	0.04
7.5 (137)	7.1 (64)	0.68
0.4 (8)	0.7 (6)	0.57
14.7 (269)	13.9 (126)	0.56
72.7 (1330)	76.1 (691)	0.06
4.7 (86)	5.6 (51)	0.30
60.5 ± 8.3	61.0 ± 8.0	0.18
	$(n=1829)$ 60.2 ± 10.1 $68.0 (1243)$ 25.2 ± 3.0 $22.6 (414)$ $8.4 (154)$ $62.9 (1150)$ $24.3 (445)$ $5.7 (104)$ $37.5 (685)$ $11.7 (213)$ $50.9 (931)$ $16.5 (301)$ $9.4 (171)$ $1.3 (23)$ $7.5 (137)$ $0.4 (8)$ $14.7 (269)$ $72.7 (1330)$ $4.7 (86)$	$(n=1829)$ $(n=908)$ 60.2 ± 10.1 60.2 ± 10.0 $68.0 (1243)$ $70.0 (636)$ 25.2 ± 3.0 25.1 ± 3.0 $22.6 (414)$ $21.3 (193)$ $8.4 (154)$ $8.0 (73)$ $62.9 (1150)$ $61.6 (559)$ $24.3 (445)$ $204 (22.5)$ $5.7 (104)$ $5.8 (53)$ $37.5 (685)$ $36.9 (335)$ $11.7 (213)$ $11.1 (101)$ $50.9 (931)$ $52.0 (472)$ $16.5 (301)$ $16.6 (151)$ $9.4 (171)$ $10.1 (92)$ $1.3 (23)$ $0.4 (4)$ $7.5 (137)$ $7.1 (64)$ $0.4 (8)$ $0.7 (6)$ $14.7 (269)$ $13.9 (126)$ $72.7 (1330)$ $76.1 (691)$ $4.7 (86)$ $5.6 (51)$

6tCt2014



Baseline Lesion Characteristics (1)

	BP-SES	DP-SES	
	(Patient, n=1829;	(Patient, n=908;	Р
	Lesion, n=2495)	Lesion, n=1235)	
Target Vessel Disease Extent			0.28
1-vessel Disease	74.1 (1356)	72.2 (656)	
2-vessel Disease	21.7 (396)	21.9 (199)	
3-vessel Disease	1.8 (33)	2.3 (21)	
Left main Disease	2.4 (44)	3.5 (32)	
Baseline SYNTAX Score	11.7 ± 8.2	11.7 ± 8.5	0.99
Number of Target Lesions			0.88
1	68.7 (1257)	68.6 (623)	
2	27.6 (504)	27.1 (246)	
3	3.4 (63)	4.0 (36)	
4	0.3 (5)	0.3 (3)	
Number of Target Lesion per Patient	1.35 ± 0.56	1.36 ± 0.57	0.88
Target Vessel Location			0.39
Left Main Artery	1.8 (44)	2.6 (32)	
Left Anterior Descending Artery	45.6 (1138)	44.5 (550)	
Left Circumflex Artery	22.6 (563)	22.8 (281)	
Right Coronary Artery	30.1 (750)	30.1 (372)	





Baseline Lesion Characteristics (2)

	BP-SES	DP-SES	
	(Patient, n=1829;	(Patient, n=908;	Р
	Lesion, n=2495)	Lesion, n=1235)	
ACC/AHA Lesion Classification B2+C	83.5 (2083)	85.1 (1051)	0.21
Complex Lesions	44.4 (1109)	46.2 (571)	0.30
Bifurcation Lesion	31.9 (797)	33.1 (409)	0.48
Ostial Lesion	1.0 (25)	0.7 (9)	0.41
Total Occlusion	12.3 (306)	12.2 (150)	0.92
Severely Tortuous or Angulated Lesion	2.3 (57)	2.4 (30)	0.78
Moderate to Heavy Calcification	2.7 (66)	3.3 (41)	0.25
Preprocedural TIMI Flow			0.37
0	12.3 (307)	12.2 (151)	
1	1.8 (44)	1.5 (18)	
2	5.3 (133)	4.1 (51)	
3	80.6 (2011)	82.2 (1015)	
Preprocedural QCA			
Reference Vessel Diameter, mm	2.79 ± 0.47	2.79 ± 0.44	0.85
Lesion Length, mm	20.6 ± 12.3	21.2 ± 12.9	0.25
Minimal Lumen Diameter, mm	0.80 ± 0.51	0.81 ± 0.51	0.78
Diameter Stenosis, %	71.6 ± 16.9	71.6 ± 16.6	0.96



*Complex lesions were defined by presence of at least one of the following lesion characteristics: unprotected left main coronary artery, bifurcation, ostial lesion, total occlusion, severely tortuous or angulated lesion, and moderate to heavy calcification.



Procedural Characteristics and Results

	BP-SES	DP-SES	
	(Patient, n=1829;	(Patient, n=908;	P
	Lesion, n=2495)	Lesion, n=1235)	
Transradial Approach	92.7 (1696)	93.5 (849)	0.46
Use of IVUS and/or OCT	3.3 (60)	3.1 (28)	0.78
Balloon Predilation	79.3 (1979)	82.2 (1015)	0.04
Stents per Patient	1.70 ± 0.86	1.75 ± 0.89	0.19
Stents per Lesion	1.26 ± 0.50	1.29 ± 0.52	0.12
≥ 3 Stents Implanted per Patient	15.7 (287)	17.8 (162)	0.15
Stent Diameter, mm	3.05 ± 0.44	3.04 ± 0.40	0.35
Total Stent Length per Patient, mm	41.1 ± 24.4	42.7 ± 24.8	0.11
Total Stent Length per Lesion, mm	30.4 ± 15.8	31.4 ± 16.5	0.07
Postdilation	51.4 (1282)	46.2 (571)	0.003
Postprocedural TIMI 3 Flow	99.5 (2482)	99.4 (1228)	0.86
Postprocedural QCA			
Minimal Lumen Diameter, mm			
In-stent	2.54 ± 0.42	2.57 ± 0.40	0.07
In-segment	2.38 ± 0.46	2.39 ± 0.44	0.36
Diameter Stenosis, %			
In-stent	8.4 ± 5.2	8.4 ± 5.5	0.94
In-segment	11.7 ± 7.2	12.0 ± 7.7	0.17
Residual SYNTAX Score	3.3 ± 5.1	3.2 ± 5.6	0.74
Device Success	99.5 (3116)	99.6 (1589)	0.62
Lesion Success	99.3 (2478)	99.4 (1228)	0.67
Procedure Success	95.8 (1752)	95.6 (868)	0.81
			ESEARCH

FOUNDATION




Primary Endpoint: TLF at 1 Year (Cardiac Death, TVMI, and CI-TLR)



Zone of noninferiority

Pre-specified margin = 3.7%




Primary Noninferiority Endpoint Met






Target Lesion Failure Through 1 Year







TLF Components and PoCE Through 1 Year




PoCE = All Cause Death + All MI + Any Revascularization

2014

CARDIOVASCULAR RESEARCH FOUNDATION


TLF and Components at 1 Year







Def/Prob Stent Thrombosis at 1 Year





Independent Predictors of 1-Year TLF by Multivariable Cox Regression Analysis

Variables	Hazard Ratio [95% CI]	Р
Emergent PCI for AMI	2.455 [1.435, 4.198]	0.001
Baseline SYNTAX Score	1.029 [1.010, 1.047]	0.002
Total Stent Length per Patient	1.009 [1.003, 1.015]	0.003
Lesion Unsuccessful	4.324 [1.876, 9.967]	0.0006





TLF Among Subgroups at 1 Year

	Target Lesion Failure - Events/Total (%)				Relative Risk	p Value for Ini
	BP-SES	DP-SES	p Value		(95% CI)	
Age						
<65 years	73/1242 (5.9)	36/618 (5.8)	0.96	_	1.01 (0.68-1.49)	0.81
≥65 years	42/587 (7.2)	19/290 (6.6)	0.74	_	1.09 (0.65-1.84)	0.01
Gender						
Male	69/1243 (5.6)	41/636 (6.4)	0.43	_ _	0.86 (0.59-1.25)	0.10
Female	46/586 (7.8)	14/272 (5.1)	0.15		1.53 (0.85-2.73)	0.10
Rady mass index						
Body mass index <30	108/1682 (6.4)	51/828 (6.2)	0.80		1.04 (0.76-1.44)	
≥30	5/114 (4.4)	4/65 (6.2)	0.73		0.71 (0.20-2.56)	0.57
	0,111(1.1)	1,00 (0.2)	0.10		0.11 (0.20 2.00)	
Diabetes mellitus						
Yes	38/414 (9.2)	14/193 (7.3)	0.43		1.27 (0.70-2.28)	0.42
No	77/1415 (5.4)	41/715 (5.7)	0.78		0.95 (0.66-1.37)	
Current smoker						
Yes	36/685 (5.3)	22/335 (6.6)	0.40		0.80 (0.48-1.34)	0.22
No	79/1144 (6.9)	33/573 (5.8)	0.36		1.20 (0.81-1.78)	0.22
Emergent PCI for AMI						
Yes	11/86 (12.8)	8/51 (15.7)	0.64		0.82 (0.35-1.89)	0.53
No	104/1743 (6.0)	47/857 (5.5)	0.62	_	1.09 (0.78-1.52)	0.53
Multivessel PCI						
Yes	37/473 (7.8)	19/252 (7.5)	0.89	_	1.04 (0.61-1.77)	
No	78/1356 (5.8)	36/656 (5.5)	0.82		1.05 (0.71-1.54)	0.98
Number of treated lesion	72/1257 (5.7)	33/623 (5.3)	0.70		1.08 (0.72-1.61)	
' ≥2	43/572 (7.5)	22/285 (7.7)	0.92		0.97 (0.59-1.60)	0.75
	10/072 (1.0)	22,200 (1.1)	0.02		0.07 (0.00 1.00)	
Preprocedural TIMI flow						
0-2	36/452 (8.0)	21/213 (9.9)	0.42		0.81 (0.48-1.35)	0.53
3	79/1377 (5.7)	34/694 (4.9)	0.43		1.17 (0.79-1.73)	0.00
Chronic total occlusion						
Yes	24/294 (8.2)	14/148 (9.5)	0.65		0.86 (0.46-1.62)	0.98
No	91/1535 (5.9)	41/759 (5.4)	0.61		1.10 (0.77-1.57)	
Bifurcation						
Yes	47/717 (6.6)	29/362 (8.0)	0.38		0.82 (0.52-1.28)	0.75
No	45/765 (5.9)	26/545 (4.8)	0.27		1.28 (0.83-1.99)	0.75
Reference vessel diameter ≤2.75 mm	70/1064 (6.6)	30/483 (6.2)	0.79		1.06 (0.70-1.60)	
>2.75 mm	45/765 (5.9)	25/424 (5.9)	0.99		1.00 (0.62-1.60)	0.85
Lesion length ≤20 mm	38/939 (4.0)	25/459 (5.4)	0.24		0.74 (0.45-1.22)	
>20 mm	38/939 (4.0) 77/890 (8.7)	25/459 (5.4) 30/448 (6.7)	0.24		1.29 (0.86-1.94)	0.09
Overall	115/1829 (6.3)	55/908 (6.1)	0.81		1.04 (0.76-1.42)	
			0.7		10	
			<		\longrightarrow	
			Favo	r BP-SES Fa	avor DP-SES	

Limitations

- We enrolled only part of the total PCI population at enrolling centers, rather than consecutive patients, and we cannot rule out some selection bias.
- The study was not powered enough to evaluate the safety endpoints at 12 months, especially stent thrombosis, warranting longer follow-up or larger trials.
- We used the old universal definition of periprocedural MI, which may overestimate the occurrence of TVMI.
- Although baseline characteristics bias has been well controlled in this randomized trial, there are some differences in procedural characteristics, e.g. rates of balloon predilation and postdilation, which might reflect minor difference between two stent platforms.







The present I-LOVE-IT 2 trial has demonstrated that the BP-SES is noninferior in terms of efficacy to DP-SES in clinical practice

Whether BP-SES improves safety with respect to lowering stent thrombosis incidence compared with DP-SES, remains to be shown in longer-term followup of this trial or in future studies







Cooperation Innovation Transition



www.citmd.com